Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer

European Journal of Cancer

Volumn 35, Issue 7, 1999, Pages 1123-1129

  Gan, Y H ^a   Zhang, Y ^a   Khoo, H E ^a   Esuvaranathan, K ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bacillus Calmette Guerin; Bladder cancer; Immunotherapy; Interferon alpha

Indexed keywords

ALPHA INTERFERON; BCG VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL CULTURE; FEMALE; HELPER CELL; INTRAVESICAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BCG VACCINE; BIOLOGICAL RESPONSE MODIFIERS; CELL DIVISION; FEMALE; IMMUNOTHERAPY; INTERFERON-ALPHA; MICE; MICE, INBRED C57BL; URINARY BLADDER NEOPLASMS;

EID: 0033166395     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00057-X     Document Type: Article

References (28)

1. Brosman SA. Bacillus Calmette-Guerin immunotherapy: Techniques and results. Urol Clin North Am 1992, 19, 557-564.
2. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976, 16, 180-183.
3. Lamm DL. Complications of Bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992, 19, 565-572.
4. Glashan RW. A randomized controlled study of intravesical α- 2b-interferon in carcinoma in situ of the bladder. J Urol 1990, 144, 658-661.
5. Torti FM, Shortliffe RD, Williams RD, et al. Alpha-interferon in superficial bladder cancer: A Northern California oncology group study. J Clin Oncol 1988, 6, 476-483.
6. Sargent ER, Williams RD. Immunotherapeutic alternatives in superficial bladder cancer: Interferon, interleukin-2 and keyholelimpet hemocyanin. Urol Clin North Am 1992, 19, 581-589.
7. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990, 144, 53-58.
8. Lamm DL. Open questions on mechanisms. Eur Urol 1992, 21(Suppl. 2), 28.
9. Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ. T- Cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993, 150, 1018-1023.
10. Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette- Guerin (BCG) immunotherapy. Clin Exp Immunol 1995, 99, 369-375.
11. Patard JJ, Chopin DK, Boccon Gibod L. Mechanisms of action of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. World J Urol 1993, 11, 165-168.
12. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992, 147, 1636-1642.
13. Borden EC, Groveman DS, Nasu T, Reznikoff C, Bryan GT. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J Urol 1992, 132, 800-803.
14. Sen GC, Lengyel P. Minireview. The interferon system. J Biol Chem 1992, 267, 5017-5020.
15. Carballido J, Molto L, Manzano L, Olivier C, Salmeron O, Alverez-mon M. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Cancer 1993, 72, 1743-1748.
16. Pryor K, Stricker P, Russell P, Golovsky D, Penny R. Anti- Proliferative effects of Bacillus Calmette-Guerin and interferon α2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 1995, 41, 309-316.
17. Zhang Y, Khoo HE, Esuvaranthan K. Effects of Bacillus Calmette-Guerin and interferon-a-2B on human bladder cancer in vitro. Int J Cancer 1997, 71, 851-857.
18. Belldegrun AS, Franklin JR, O'Donnell MA, et al. Superficial bladder cancer: The role of interferon-α. J Urol 1998, 159, 1793-1801.
19. Riggs DR, Tarry WF, Dehaven JI, Sosnowski J, Lamm DL. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J Urol 1992, 147, 212-214.
20. Ratliff TL, Gerber A, Ritchey JK, Nadler R. Modulation of bladder tumour cytokine production by BEC. J Urol 1994, 151, 1152 (Abstr. 515A).
21. Tilg H, Peschel C. Interferon alpha and its effects on the cytokine cascade: A pro- and anti-inflammatory cytokine. Leuk Lymphoma 1996, 23, 55-60.
22. Noraz N, Lathey JL, Spector SA. Human cytomegalovirus-associated immunosuppression is mediated through interferon alpha. Blood 1997, 89, 2443-2452.
23. Shenoy M, Baron S, Wu B, Goluszko E, Christadoss P. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia. J Immunol 1995, 154, 6203-6208.
24. Zlotta AR, Drowart A, Van Vooren JP, et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol 1997, 157, 492-498.
25. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated anti-tumour activity. J Urol 1987, 137, 155-158.
26. McAveney KM, Gomella LG, Lattime EC. Induction of TH1 and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumour MB49 and BCG immunotherapy. Cancer Immunol Immunother 1994, 39, 401-406.
27. + T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989, 112, 161-182.
28. Sander B, Skansen-Saphir U, Damm O, Hakansson L, Andersson J. Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guerin. Immunology 1995, 86, 512-518.